GeorgeThompson IIIMD

Infectious Disease • Sacramento, CA

Professor, University of California - Davis Medical Center

Join to view full profile

Dr. Thompson III is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Thompson III's full profile

Already have an account?

Office
4150 V St
Ste G500
Sacramento, CA 95817
Phone+1 916-734-3741

Fax+1 530-752-8692

Education & Training

University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Infectious Disease, 2007 - 2009
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineChief Residency, Internal Medicine, 2006 - 2007
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineResidency, Internal Medicine, 2003 - 2006
University of Missouri-Columbia School of MedicineClass of 2003

Certifications & Licensure

CA State Medical License 2009 - 2025
TX State Medical License 2006 - 2009
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis Start of enrollment: 2007 Mar 07
Completed
Phase 3
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections Start of enrollment: 2007 Mar 08
Completed
Phase 3
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi Start of enrollment: 2008 Apr 22
Completed
Phase 3
Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis Start of enrollment: 2014 Sep 01
Completed
Phase 2
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension Start of enrollment: 2016 Jul 26
Completed
Phase 2
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment Start of enrollment: 2017 Apr 01
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

5 citations
Epithelial hypoxia maintains colonization resistance against Candida albicans.
Hannah P Savage, Derek J Bays, Connor R Tiffany, Mariela A F Gonzalez, Eli J Bejarano
Cell Host & Microbe. 2024-07-10
140 citations
Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation.
Guochun Jiang, Erica A. Mendes, Philipp Kaiser, Daniel P. Wong, Yuyang Tang
Plos Pathogens. 2015-07-30
24 citations
Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases.
George R Thompson 3rd, David R Boulware, Nathan C Bahr, Cornelius J Clancy, Thomas S Harrison
Open Forum Infectious Diseases. 2022-06-01

Committees

Panelist, IDSA Journal Club 2009 - Present

Professional Memberships